

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

DUSA PHARMACEUTICALS INC

Form 4

June 28, 2001

FORM 4

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. SEE Instruction 1(b).

OMB Number: 3235-0287
Estimated average burden hours per response ... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person*

Cooper Hill Partners, LLC

(Last) (First) (Middle)

230 Park Avenue

(Street)

New York, NY 10169

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

DUSA Pharmaceuticals Inc. DUSA

3. IRS or Social Security Number of Reporting Person (Voluntary)

4. Statement for Month/Year

5/01

5. If Amendment, Date of Original (Month/Year)

6. Relationship of Reporting Person(s) to Issuer (Check all applicable)

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

- Director
- 10% Owner
- Officer (give title below)
- Other (specify below)

7. Individual or Joint/Group Filing (Check Applicable Line)

- Form filed by One Reporting Person
- Form filed by More than One Reporting Person

TABLE I--NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED

1. Title of Security (Instr. 3)	2. Trans- action Date (Month/ Day/ Year)	3. Trans- action Code (Instr. 8) ----- Code V	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) ----- Amount (A) or Price (D)
Common Stock, par value \$.01 per share	4/4/01	P	13,100 (A) \$11.3125
Common Stock, par value \$.01 per share	4/4/01	S	87,100 (D) \$11.3125
Common Stock, par value \$.01 per share	5/16/01	P	41,400 (A) \$13.52
Common Stock, par value \$.01 per share	5/29/01	P	81,100 (A) \$12.10
Common Stock, par value \$.01 per share	6/4/01	P	20,600 (A) \$11.70
Common Stock, par value \$.01 per share	6/4/01	S	25,200 (D) \$11.70

5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1,726,800	(I)	See Explanation of Responses

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

 Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, SEE Instruction 4 (b) (v).

(Over)
 SEC 1474 (7-96)
 Page 1 of 2

FORM 4 (continued)

TABLE II - DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED (E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8) Code V	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)
				(A) (D)

6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at End of Month (Instr. 4)
Date	Expiration Date	Title	Amount or Number of Shares

